White Dot Syndromes

  • Jyotirmay Biswas
  • Radha Annamalai


Visual loss with an etiology that is localized to the posterior segment of the eye and more precisely the choroid needs to be further analyzed to discern whether the disease is caused by an autoimmune process or infection. White dot syndromes (WDS) or inflammatory chorioretinopathies are an overlapping group of inflammatory disorders with clinical features that share the common presence of discrete, multiple, well-circumscribed, yellow-white lesions at the level of the retina, retinal pigment epithelium (RPE), choriocapillaries, and choroid. The various diagnoses are differentiated by history, clinical appearance, laterality, and imaging. Laboratory investigations are not routinely necessary for their diagnosis but are essential for monitoring therapy-related side effects. A significant percentage of patients with WDS have a prodromal viral-like illness that triggers the onset of the ocular condition. Although self-limiting, they need to be followed up closely for complications such as scarring and choroidal neovascular membranes (CNVM). Patients with WDS present with sudden blurring of vision often associated with photopsia, floaters, scotomata, and metamorphopsia.


Retinal Pigment Epithelium Cystoid Macular Edema Indocyanine Green Angiography Fluocinolone Acetonide Fluorescein Angiogram 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jyotirmay B, Jafferji SS, Sudharshan S, Kalpana B. Clinical profile, treatment, and visual outcome of ampiginous choroiditis. Ocul Immunol Inflamm. 2010;18(1):46–51.PubMedGoogle Scholar
  2. 2.
    Biswas J, Narain S, Das D, Ganesh SK. Pattern of uveitis in a referral uveitis clinic in India. Int Ophthalmol. 1996–1997;20(4):223–8.Google Scholar
  3. 3.
    Laatikainen L, Jokinen E. Immunological studies on serpiginous choroiditis. Graefes Arch Clin Exp Ophthalmol. 1982;219:131–4.PubMedGoogle Scholar
  4. 4.
    Das D, Bhattacharjee H, Bhattacharyya PK, Jain L, Panicker MJ, Das K, Deka AC. Pattern of uveitis in North East India: a tertiary eye care center study. Indian J Ophthalmol. 2009;57:144–6.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Gupta V, Gupta A, Rao NA. Intraocular tuberculosis-an update. Surv Ophthalmol. 2007;52:561–87.PubMedGoogle Scholar
  6. 6.
    Nazari Khanamiri H, Rao NA. Serpiginous choroiditis and infectious multifocal serpiginoid choroiditis. Surv Ophthalmol. 2013;58(3):203–32.PubMedGoogle Scholar
  7. 7.
    Priya K, Madhavan HN, Reiser BJ, et al. Association of herpesviruses in the aqueous humor of patients with serpiginous choroiditis: a polymerase chain reaction-based study. Ocul Immunol Inflamm. 2002;10:253–61.PubMedGoogle Scholar
  8. 8.
    Abrez H, Biswas J, Sudharshan S. Clinical profile, treatment, and visual outcome of serpiginous choroiditis. Ocul Immunol Inflamm. 2007;15(4):325–35.PubMedGoogle Scholar
  9. 9.
    Sahu DK, Rawoof A, Sujatha B. Macular serpiginous choroiditis. Indian J Ophthalmol. 2002;50(3):189–96.PubMedGoogle Scholar
  10. 10.
    Shi Ji-chuan, Zheng Yue-zhong, Liu Bei. Clinical features and treatment of serpiginous choroiditis. Chin J Pract Ophthalmol. 2008;26:3.Google Scholar
  11. 11.
    Bansal R, Gupta A, Gupta V. Imaging in the diagnosis and management of serpiginous choroiditis. Int Ophthalmol Clin. 2012;52(4):229–36.PubMedGoogle Scholar
  12. 12.
    Agrawal RV, Biswas J, Gunasekaran D. Indocyanine green angiography in posterior uveitis. Indian J Ophthalmol. 2013;61(4):148–59.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Cardillo Piccolino F, Grosso A, Savini E. Fundus autofluorescence in serpiginous choroiditis. Arch Clin Exp Ophthalmol. 2009;2:179–85.Google Scholar
  14. 14.
    Gallaghe MJ, Yilmaz T, Cervantes-Castañeda RA, Foster CS. The characteristic features of optical coherence tomography in posterior uveitis. Br J Ophthalmol. 2007;91:1680–5.Google Scholar
  15. 15.
    Vasconcelos-Santos DV, Rao K, Davies JB, Sohn EH, Rao NA. Clinical features of tuberculous serpiginouslike choroiditis in contrast to classic serpiginous choroiditis. Arch Ophthalmol. 2010;128:853–8.PubMedGoogle Scholar
  16. 16.
    Bansal R, Gupta A, Gupta V, Dogra MR, Sharma A, Bambery P. Tubercular serpiginous-like choroiditis presenting as multifocal serpiginoid choroiditis. Ophthalmology. 2012;119(11):2334–42.PubMedGoogle Scholar
  17. 17.
    Sudharshan S, Ganesh SK, Balu G, Mahalakshmi B, Therese LK, Madhavan HN, Biswas J. Utility of QuantiFERON-TB Gold test in diagnosis and management of suspected tubercular uveitis in India. Int Ophthalmol. 2012;32(3):217–23.PubMedGoogle Scholar
  18. 18.
    Bhuibhar SS, Biswas J. Nested PCR-positive tubercular ampiginous choroiditis: a case report. Ocul Immunol Inflamm. 2012;20(4):303–5.PubMedGoogle Scholar
  19. 19.
    Dworkin LL, Gibler TM, Van Gelder RN. Real-time quantitative polymerase chain reaction diagnosis of infectious posterior uveitis. Arch Ophthalmol. 2002;120(11):1534–9.PubMedGoogle Scholar
  20. 20.
    Rothova A, de Boer JH, Ten Dam-van Loon NH, Postma G, de Visser L, Zuurveen SJ, Schuller M, Weersink AJ, van Loon AM, de Groot-Mijnes JD. Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis. Ophthalmology. 2008;115:306–11.PubMedGoogle Scholar
  21. 21.
    Nikos N, Ioannis H, Simina P, Nikos G, Nikos E, Tasos K. Intravenous pulse methylprednisolone therapy for acute treatment of serpiginous choroiditis. Ocul Immunol Inflamm. 2005;14:29–33.Google Scholar
  22. 22.
    Seth RK, Gaudio PA. Treatment of serpiginous choroiditis with intravitreous fluocinolone acetonide implant. Ocul Immunol Inflamm. 2008;16(3):103–5.PubMedGoogle Scholar
  23. 23.
    Vianna RNG, Özdal PC, Deschênes J, Burnier MN. Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. Can J Ophthalmol. 2006;41:183–9.PubMedGoogle Scholar
  24. 24.
    Araujo AAQ, Wells AP, Dick AD, Forrester JV. Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome. Br J Ophthalmol. 2000;84:979–82.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991;98:944–51.PubMedGoogle Scholar
  26. 26.
    Sobaci G, Bayraktar Z, Bayer A. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm. 2005;13:59–66.PubMedGoogle Scholar
  27. 27.
    Akpek KE, Ilhan-Sarac O. New treatments for serpiginous choroiditis. Retina and vitreous disorders. Curr Opin Ophthalmol. 2003;14(3):128–31.PubMedGoogle Scholar
  28. 28.
    Gass JDM. Acute posterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol. 1968;80:177–85.PubMedGoogle Scholar
  29. 29.
    Savino PJ, Weinberg RJ, Yassin JC, Pilkerton AR. Diverse manifestations of acute posterior multifocal placoid pigment epitheliopathy. Am J Ophthalmol. 1974;77:659–62.PubMedGoogle Scholar
  30. 30.
    Oleszczuk JD, Saeed MU. Neurological symptoms associated with acute multifocal placoid pigment epitheliopathy: treatment dilemma and diagnostic issues. Semin Ophthalmol. 2015;30:238–40. Posted online on 31 Oct 2013.PubMedGoogle Scholar
  31. 31.
    Montero JA, Ruiz-Moreno JM, Fernandez-Munoz M. Spectral domain optical coherence tomography findings in acute posterior multifocal placoid pigment epitheliopathy. Ocul Immunol Inflamm. 2011;19(1):48–50.PubMedGoogle Scholar
  32. 32.
    Abu-Yaghi NE, Hartono SP, Hodge DO, Pulido JS, Bakri SJ. White dot syndromes: a 20-year study of incidence, clinical features, and outcomes. Ocul Immunol Inflamm. 2011;19:426–30.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Lee GE, Lee BW, Rao NA, Fawzi AA. Spectral domain optical coherence tomography and autofluorescence in a case of acute posterior multifocal placoid pigment epitheliopathy mimicking Vogt-Koyanagi-Harada disease: case report and review of literature. Ocul Immunol Inflamm. 2011;19(1):42–7.PubMedGoogle Scholar
  34. 34.
    Servat JJ, Mears KA, Black EH, Huang JJ. Biological agents for the treatment of uveitis. Expert Opin Biol Ther. 2012;12(3):311–28.PubMedGoogle Scholar
  35. 35.
    Yenerel NM, Gorgun E, Dinc UA, Oncel M. Treatment of cystoid macular edema due to acute posterior multifocal placoid pigment epitheliopathy. Ocul Immunol Inflamm. 2008;16(1–2):67–71.PubMedGoogle Scholar
  36. 36.
    Baarsma GS, Priem HA, Kijlstra A. Association of birdshot retinochoroidopathy and HLA-A29 antigen. Curr Eye Res. 1990;9(Suppl):63–8.PubMedGoogle Scholar
  37. 37.
    Shah KH, Levinson RD, Yu F, Goldhardt R, Gordon LK, Gonzales CR, Heckenlively JR, Kappel PJ, Holland GN. Birdshot chorioretinopathy. Surv Ophthalmol. 2005;50(6):519–41.PubMedGoogle Scholar
  38. 38.
    Keane PA, Allie M, Turner SJ, Southworth HS, Sadda SR, Murray PI, et al. Characterization of birdshot chorioretinopathy using extramacular enhanced depth optical coherence tomography. JAMA Ophthalmol. 2013;131(3):341–50.PubMedGoogle Scholar
  39. 39.
    Durrani K, Foster CS. Fundus Autofluorescence Imaging in Posterior Uveitis. Semin Ophthalmol. 2012;27(5–6):228–35.PubMedGoogle Scholar
  40. 40.
    Cimino L, Tran VT, Herbort CP. Importance of visual field testing in the functional evaluation and follow-up of birdshot chorioretinopathy. Ophthalmic Res. 2002;34(S1):141.Google Scholar
  41. 41.
    Comander J, Loewenstein J, Sobrin L. Diagnostic testing and disease monitoring in birdshot chorioretinopathy. Semin Ophthalmol. 2011;26(4–5):329–36.PubMedGoogle Scholar
  42. 42.
    Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 1994;101(5):822–31.PubMedGoogle Scholar
  43. 43.
    Cervantes-Castañeda RA, Gonzalez-Gonzalez LA, Cordero-Coma M, Yilmaz T, Foster CS. Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12-month follow-up. Br J Ophthalmol. 2013;97(5):637–43.PubMedGoogle Scholar
  44. 44.
    Rothova A, Ossewaarde-van Norel A, Los LI, Berendschot TT. Efficacy of low-dose methotrexate treatment in birdshot chorioretinopathy. Retina. 2011;31(6):1150–5. [Medline].PubMedGoogle Scholar
  45. 45.
    Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology. 2005 Jun;112(6):1066–71.Google Scholar
  46. 46.
    Menezo V, Taylor SR. Birdshot uveitis: current and emerging treatment options. Clin Ophthalmol. 2014;8:73–81.PubMedCentralPubMedGoogle Scholar
  47. 47.
    Oh KT, Christmas NJ, Folk JC. Birdshot retinochoroiditis: long term follow-up of a chronically progressive disease. Am J Ophthalmol. 2002;133(5):622–9.PubMedGoogle Scholar
  48. 48.
    Morgan CM, Schatz H. Recurrent multifocal choroiditis. Ophthalmology. 1986;93:1138–47.PubMedGoogle Scholar
  49. 49.
    Spaide RF, Sugin S, Yannuzzi LA, De Rosa JT. Epstein-Barr virus antibodies in multifocal choroiditis and panuveitis. Am J Ophthalmol. 1991;112:410–3.PubMedGoogle Scholar
  50. 50.
    Quillen DA, Davis JB, Gottlieb JL, et al. The white dot syndromes. Am J Ophthalmol. 2004;137(3):538–50.PubMedGoogle Scholar
  51. 51.
    Bryan RG, Freund KB, Yannuzzi LA, Spaide RF, Huang SJ, Costa DL. Multiple evanescent white dot syndrome in patients with multifocal choroiditis. Retina. 2002;22(3):317–22. [PubMed].PubMedGoogle Scholar
  52. 52.
    Spaide RF, Yannuzzi LA, Freund KB. Linear streaks in multifocal choroiditis and panuveitis. Retina. 1991;11:229–31.PubMedGoogle Scholar
  53. 53.
    Kotsolis AI, Killian FA, Ladad ID, Yannuzzi LA. Fluorescein angiography and optical coherence tomography concordance for choroidal neovascularisation in multifocal choroiditis. Br J Ophthalmol. 2010;94:11.Google Scholar
  54. 54.
    Vance SK, Khan S, Klancnik JM, Freund KB. Characteristic spectral-domain optical coherence tomography findings of multifocal choroiditis. Retina. 2011;31(4):717–23.PubMedGoogle Scholar
  55. 55.
    Khorram KD, Jampol LM, Rosenberg MA. Blind spot enlargement as a manifestation of multifocal choroiditis. Arch Ophthalmol. 1991;109:1403–7.PubMedGoogle Scholar
  56. 56.
    Dreyer RF, Gass JDM. Multifocal choroiditis and panuveitis. A syndrome that mimics ocular histoplasmosis. Arch Ophthalmol. 1984;102(12):1776–84.PubMedGoogle Scholar
  57. 57.
    Ongchin S, Keene CD, Van Gelder R, Vemulakonda GA. A diagnostic dilemma: infectious versus noninfectious multifocal choroiditis with panuveitis. J Ophthalmic Inflamm Infect. 2013;3(1):26.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Shakoor A, Vitale AT. Imaging in the diagnosis and management of multifocal choroiditis and punctate inner choroidopathy. Int Ophthalmol Clin. 2012;52(4):243–56.PubMedGoogle Scholar
  59. 59.
    Parodi MB, Iacono P, Kontadakis DS, Zucchiatti I, Cascavilla ML, Bandello F. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. Arch Ophthalmol. 2010;128(9):1100–3.PubMedGoogle Scholar
  60. 60.
    Parnell JR, Jampol LM, Yannuzzi LA, et al. Differentiation between presumed ocular histoplasmosis syndrome and multifocal choroiditis with panuveitis based on morphology of photographed fundus lesions and fluorescein angiography. Arch Ophthalmol. 2001;119:208–12.PubMedGoogle Scholar
  61. 61.
    Fung AT, Pal S, Yannuzzi NA, Christos P, Cooney M, Slakter JS, Klancnik Jr JM, Freund KB, Cunningham Jr ET, Yannuzzi LA. Multifocal choroiditis without panuveitis: clinical characteristics and progression. Retina. 2014;34(1):98–107.PubMedGoogle Scholar
  62. 62.
    Watzke RC, Packer AJ, Folk JC, Benson WE, Burgess D, Ober RR. Punctate inner choroidopathy. Am J Ophthalmol. 1984;98(5):572–84.PubMedGoogle Scholar
  63. 63.
    Tiedman JS. Epstein-Barr viral antibodies in multifocal choroiditis and panuveitis. Am J Ophthalmol. 1987;3:659–63.Google Scholar
  64. 64.
    Spaide RF, Skerry JE, Yannuzzi LA, DeRosa JT. Lack of the HLA-DR2 specificity in multifocal choroiditis and panuveitis. Br J Ophthalmol. 1990;3:536–7.Google Scholar
  65. 65.
    Patel KH, Birnbaum AD, Tessler HH, Goldstein DA. Presentation and outcome of patients with punctate inner choroidopathy at a tertiary referral center. Retina. 2011;31(7):1387–91.PubMedGoogle Scholar
  66. 66.
    Amer R, Lois N. Punctate inner choroidopathy. Surv Ophthalmol. 2011;56(1):36–53.PubMedGoogle Scholar
  67. 67.
    Gerstenblith AT, Thorne JE, Sobrin L, Do DV, Shah SM, Foster CS. Punctate inner choroidopathy: a survey analysis of 77 persons. Ophthalmology. 2007;114:1201–4.PubMedGoogle Scholar
  68. 68.
    Leung AK, Weisbrod DJ, Schwartz C. Intravitreal ranibizumab in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy. Can J Ophthalmol. 2010;45(3):300–1.PubMedGoogle Scholar
  69. 69.
    Tiffin PA, Maini R, Roxburgh ST, et al. Indocyanine green angiography in a case of punctate inner choroidopathy. Br J Ophthalmol. 2002;80:90–1.Google Scholar
  70. 70.
    Chen SN, Hwang JF. Ocular coherence tomographic and clinical characteristics in patients of punctuate inner choroidopathy associated with zonal outer retinopathy. Ocul Immunol Inflamm. 2014;22:263–9. Posted online on 19 Dec 2013.PubMedGoogle Scholar
  71. 71.
    Zhang X, Zuo C, Li M, Chen H, Huang S, Wen F. Spectral-domain optical coherence tomographic findings at each stage of punctate inner choroidopathy. Ophthalmology. 2013;120(12):2678–83.PubMedGoogle Scholar
  72. 72.
    Kramer M, Priel E. Fundus autofluorescence imaging in multifocal choroiditis: beyond the spots. Ocul Immunol Inflamm. 2014;22:349–55. Posted online on 11 Dec 2013.PubMedGoogle Scholar
  73. 73.
    Riaz KM, Jampol LM, Mirza RG. Fundus autofluorescence imaging in punctate inner choroidopathy with blind spot enlargement. Ocul Immunol Inflamm. 2012;20(6):460–3.PubMedGoogle Scholar
  74. 74.
    Essex RW, Wong J, Fraser-Bell S, Sandbach J, Tufail A, Bird AC, Dowler J. Punctate inner choroidopathy: clinical features and outcomes. Arch Ophthalmol. 2010;128(8):982–7.PubMedGoogle Scholar
  75. 75.
    Levy J, Shneck M, Klemperer I, Lifshitz T. Punctate inner choroidopathy: resolution after oral steroid treatment and review of the literature. Can J Ophthalmol. 2005;40(5):605–8.PubMedGoogle Scholar
  76. 76.
    Brueggeman RM, Noffke AS, Jampol LM. Resolution of punctate inner choroidopathy lesions with oral prednisone therapy. Arch Ophthalmol. 2002;120(7):996.PubMedGoogle Scholar
  77. 77.
    Fong KC, Thomas D, Amin K, Inzerillo D, Horgan SE. Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy. Eye (Lond). 2008;22(4):528–33.Google Scholar
  78. 78.
    Chan WM, Lai TY, Lau TT, Lee VY, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series. Retina. 2008;28(1):71–80.PubMedGoogle Scholar
  79. 79.
    Lowder C, Belfort Jr R, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM. Ozurdex huron study group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–53.PubMedGoogle Scholar
  80. 80.
    Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Ophthalmology. 2011;118(10):1916–26.PubMedCentralPubMedGoogle Scholar
  81. 81.
    Turkcuoglu P, Chang PY, Rentiya ZS, Channa R, Ibrahim M, Hatef E, Sophie R, Sadaka A, Wang J, Sepah YJ, Do DV, Foster CS, Nguyen QD. Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. Ocul Immunol Inflamm. 2011;19(4):286–92.PubMedGoogle Scholar
  82. 82.
    Ip M, Gorin MB. Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide. Am J Ophthalmol. 1996;122(4):594–5.PubMedGoogle Scholar
  83. 83.
    Nussenblatt RB, Coleman H, Jirawuthiworavong G, et al. The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin). Acta Ophthalmol Scand. 2007;85:230–1.PubMedGoogle Scholar
  84. 84.
    Cirino AC, Mathura Jr JR, Jampol LM. Resolution of activity (choroiditis and choroidal neovascularization) of chronic recurrent punctate inner choroidopathy after treatment with interferon B-1A. Retina. 2006;26(9):1091–2.PubMedGoogle Scholar
  85. 85.
    Mangat SS, Ramasamy B, Prasad S, Walters G, Mohammed M, Mckibbin M. Resolution of choroidal neovascularization secondary to punctate inner choroidopathy (PIC) with intravitreal anti-VEGF agents: a case series. Semin Ophthalmol. 2011;26(1):1–3.PubMedGoogle Scholar
  86. 86.
    Chatterjee S, Gibson JM. Photodynamic therapy: a treatment option in choroidal neovascularisation secondary to punctate inner choroidopathy. Br J Ophthalmol. 2003;87(7):925–7.PubMedCentralPubMedGoogle Scholar
  87. 87.
    Ehlers JP, Maldonado R, Sarin N, Toth CA. Treatment of non-age-related macular degeneration submacular diseases with macular translocation surgery. Retina. 2011;31(7):1337–46.PubMedGoogle Scholar
  88. 88.
    Jampol LM, Sieving PA, Pugh D, et al. Multiple evanescent white dot syndrome. I. Clinical findings. Arch Ophthalmol. 1984;102:671–4.PubMedGoogle Scholar
  89. 89.
    Borruat FX, Herbort CP, Spertini F, et al. HLA typing in patients with multiple evanescent white dot syndrome (MEWDS). Ocul Immunol Inflamm. 1998;6:39–41.PubMedGoogle Scholar
  90. 90.
    Gross NE, Yannuzzi LA, Freund KB, Spaide RF, Amato GP, Sigal R. Multiple evanescent white dot syndrome. Arch Ophthalmol. 2006;124(4):493–500.PubMedGoogle Scholar
  91. 91.
    Joseph A, Rahimy E, Freund KB, Sorenson JA, Sarraf D. Fundus autofluorescence and photoreceptor bleaching in multiple evanescent white dot syndrome. Ophthalmic Surg Lasers Imaging Retina. 2013;44(6):588–92.PubMedGoogle Scholar
  92. 92.
    Hangai M, Fujimoto M, Yoshimura N. Features and function of multiple evanescent white dot syndrome. Arch Ophthalmol. 2009;127(10):1307–13.PubMedGoogle Scholar
  93. 93.
    Hua R, Chen K, Liu LM, Liu NN, Chen L, Teng WP. Multi-modality imaging on multiple evanescent white dot syndrome-A Spectralis Study. Int J Ophthalmol. 2012;5(5):644–7.PubMedCentralPubMedGoogle Scholar
  94. 94.
    Sieving PA, Fishman GA, Jampol LM, Pugh D. Multiple evanescent white dot syndrome. II. Electrophysiology of the photoreceptors during retinal pigment epithelial disease. Arch Ophthalmol. 1984;102:675–9.PubMedGoogle Scholar
  95. 95.
    Palestine AG, Nussenblatt RB, Parver LM, Knox DL. Progressive subretinal fibrosis and uveitis. Br J Ophthalmol. 1984;68:667–73.PubMedCentralPubMedGoogle Scholar
  96. 96.
    Symeonidis C, Dastiridou A, Konidaris V, Brazitikos P, Androudi S. Subretinal fibrosis and uveitis: a spectral domain OCT study of its evolution and the minimal therapeutic effect of the off-label treatment with ranibizumab. Ocul Immunol Inflamm. 2014;22:497–500.PubMedGoogle Scholar
  97. 97.
    Monson DM, Smith JR. Acute zonal occult outer retinopathy. Surv Ophthalmol. 2011;56(1):23–35.PubMedGoogle Scholar
  98. 98.
    Gass JD, Agarwal A, Scott IU. Acute zonal occult outer retinopathy: a long-term follow-up study. Am J Ophthalmol. 2002;134(3):329–39.PubMedGoogle Scholar
  99. 99.
    Kuniyoshi K, Sakuramoto H, Nakao Y, Matsumoto C, Shimomura Y. Two types of acute zonal occult outer retinopathy differentiated by dark- and light-adapted perimetry. Jpn J Ophthalmol. 2014;58:177–87.PubMedGoogle Scholar
  100. 100.
    Chai Y, Yamazaki H, Fujinami K, Tsunoda K, Yamamoto S. A case of acute zonal occult outer retinopathy with abnormal pattern visual evoked potentials. Clin Ophthalmol. 2011;5:1235–41.PubMedCentralPubMedGoogle Scholar
  101. 101.
    Krill AE, Deutman AF. Acute retinal pigment epitheliitis. Am J Ophthalmol. 1972;74:193–205.PubMedGoogle Scholar
  102. 102.
    Baillif S, Wolff B, Paoli V, Gastaud P, Mauget-Faÿsse M. Retinal fluorescein and indocyanine green angiography and spectral-domain optical coherence tomography findings in acute retinal pigment epitheliitis. Retina. 2011;31(6):1156–63.PubMedGoogle Scholar
  103. 103.
    Hsu J, Fineman MS, Kaiser RS. Optical coherence tomography findings in acute retinal pigment epitheliitis. Am J Ophthalmol. 2007;143:163–5.PubMedGoogle Scholar
  104. 104.
    Cho HJ, Lee DW, Kim CG, Kim JW. Spectral domain optical coherence tomography findings in acute retinal pigment epitheliitis. Can J Ophthalmol. 2011;46(6):498–500. [Medline].PubMedGoogle Scholar
  105. 105.
    Jee Wook Kim, Sun Young Jang, Tae Kwann Park, Young-Hoon Ohn. Short-term clinical observation of acute retinal pigment epitheliitis using spectral-domain optical coherence tomography. Korean J Ophthalmol. 2011;25(3):222–4.Google Scholar
  106. 106.
    Li D, Kishi S. Restored photoreceptor outer segment damage in multiple evanescent white dot syndrome. Ophthalmology. 2009;116:762–70.PubMedGoogle Scholar
  107. 107.
    Amin P, Cox TA. Acute macular neuroretinopathy. Arch Ophthalmol. 1998;116:112–3.PubMedGoogle Scholar
  108. 108.
    Fawzi AA, Pappuru RR, Sarraf D, et al. Acute macular neuroretinopathy: long term insights revealed by multimodal imaging. Retina. 2012;32:1500–13.PubMedGoogle Scholar
  109. 109.
    Baumuller S, Holz FG. Early spectral-domain optical coherence tomography findings in acute macular neuroretinopathy. Retina. 2012;32:409–10.PubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Sankara NethralayaPondicherryIndia
  2. 2.Ophthalmology, Sri Ramachandra Medical College & Research InstituteSri Ramachandra UniversityChennaiIndia

Personalised recommendations